-
Ginkgo Bioworks, Which Prints DNA And Creates Genetically Modified Food, Exploring SPAC Deal: Report
Friday, April 9, 2021 - 12:25pm | 796Read More...One of the largest SPACs seeking a target could be nearing a $20 billion deal to bring one of the largest privately-held biotechnology companies public. The SPAC Rumor: Bloomberg reports Ginkgo Bioworks is in talks with Soaring Eagle Acquisition Corp (NASDAQ: SRNGU), a SPAC led by Harry Sloan and...
-
Fintech Focus For July 15, 2020
Wednesday, July 15, 2020 - 7:56am | 1654Read More...Daily Perspective: I don’t think anybody should leave any bank earnings call this quarter simply feeling like the worst is absolutely behind us and it’s a rosy path ahead. - Michael Corbat Fintech Movers: The disrupted circulation of physical currency has even led to a national coin...
-
Bayer CEO Predicts 'Great Value And Growth' In Company After Monsanto Acquisition
Thursday, June 7, 2018 - 4:32pm | 383Read More...Germany drugmaker Bayer's acquisition of Monsanto closed this week after a challenging two-year-long review process. Despite creating the world's largest seed and agricultural chemicals maker, the "highly competitive environment" will remain unchanged, Bayer CEO Werner...
-
Argus Downgrades Monsanto After DOJ Blesses Bayer Merger
Monday, April 16, 2018 - 10:45am | 363Read More...The U.S. Department of Justice's move to approve German pharma company Bayer AG's acquisition of U.S.-based Monsanto Company (NYSE: MON) prompted at least one Wall Street analyst to turn bearish on the stock. The Analyst Argus' Bill Selesky downgraded Monsanto's stock rating...
-
Can Monsanto Stop The 'Billion Dollar Pest'?
Tuesday, June 27, 2017 - 2:02pm | 382Read More...Monsanto Co. Monsanto (MON) will release FQ3'17 earnings before the market opens on Wednesday, June 28th. Estimize and Wall Street are foreshadowing both EPS and Revenue to come in lower than the previous quarter. The Estimize community is more bullish in comparison to the...
-
The Prospect Of The U.S. Blocking The Bayer-Monsanto Deal Can't Be Dismissed
Tuesday, June 27, 2017 - 12:24pm | 475Read More...Susquehanna analyst Don Carson downgraded Monsanto Company (NYSE: MON) from Positive to Neutral, while raising its price target from $125 to $128. The downgrade is not a result of increasing headwinds or poor performance, but rather because the 9-percent upside from Bayer AG (ADR) (OTC: BAYRY)'s $...
-
Monsanto Terms Bayer's Revised Proposal As Inadequate And Insufficient
Tuesday, July 19, 2016 - 10:19am | 182Read More...Monsanto Company (NYSE: MON) disclosed Tuesday that its Board has unanimously rejected Bayer AG's revised proposal. The company termed it as financially inadequate and insufficient to ensure the deal certainty. However, Monsanto indicated its willingness to remain open to continued, as well...
-
Monsanto Confirms Bayer's Revised Proposal
Thursday, July 14, 2016 - 1:19pm | 139Read More...Monsanto Company (NYSE: MON) confirmed Thursday that it received a revised, non-binding proposal from Bayer AG for a possible acquisition of the company. The company indicated that its Board would review the proposal, in consultation with its financial and legal advisors. The company disclosed...
-
Jim Cramer Says Bayer-Monsanto Deal Will Be Blocked
Monday, May 23, 2016 - 11:15am | 232Read More...Shares of Monsanto Company (NYSE: MON) were trading higher by more than 5 percent on Monday at $107.24 after Bayer made public its intentions to acquire the company for $122 per share. Given the notable discount in Monsanto's trading price to the takeout offer, investors and traders could...
-
Bayer Confirms Market Speculation, Offers To Acquire Monsanto At $122/Share To 'Create A Global Agriculture Leader'
Monday, May 23, 2016 - 8:22am | 437Read More...Germany-based Bayer publicly disclosed Monday morning details of its proposed acquisition of Monsanto Company (NYSE: MON) following market speculation and stakeholder inquiries last week. Pricing Bayer confirmed it has made an all-cash offer to acquire all of Monsanto's common stock for $122 per...
-
Bayer's Monsanto Acquisition Unlikely To Happen, Says Citi
Friday, May 20, 2016 - 8:13am | 275Read More...Citi’s P.J. Juvekar believes the acquisition of Monsanto Company (NYSE: MON) by Bayer is unlikely to occur, given the potential synergies, divestitures needed, regulatory concerns and more. Juvekar maintains a Neutral rating on Monsanto, with a price target of $94. Synergies The analyst...
-
Monsanto Pops 17% Amid Multiple Takeover Reports
Thursday, May 12, 2016 - 8:11am | 185Read More...Shares of Monsanto Company (NYSE: MON) surged higher by more than 17 percent early Thursday morning after the company was named as a potential takeover target. Street Insider, citing "sources claiming to have knowledge of the situation," reported Wednesday evening that Germany-based...
-
Compugen Achieves Milestone Event With Bayer
Monday, April 18, 2016 - 2:10pm | 172Read More...Compugen Ltd. (NASDAQ: CGEN) announced on Monday it has achieved a first preclinical milestone for CGEN-15022 as part of a cancer immunotherapy agreement with Bayer. The companies entered into a collaboration and license agreement in 2013 for the development of anitbody-based cancer immune...
-
Bayer CEO Weighs In On Guidance, Listing Of Material Science Business And Syngenta
Wednesday, July 29, 2015 - 1:02pm | 314Read More...Bayer AG (ADR)(OTC: BAYRY) reported a 21 percent year-over-year rise to $1.27 billion in second-quarter profits. Marijn Dekkers, CEO of Bayer, was on CNBC to weigh in on the company's guidance and shed light on the listing of its material science arm. Guidance "We have...
-
Regeneron Earnings: Small Growth Expected, Driven By Eylea
Wednesday, May 6, 2015 - 5:30pm | 385Read More...Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is scheduled to announce its first quarter financial results on Thursday, and both the crowd and experts expect to see some growth, although the Street is slightly more bullish. According to Estimize, Wall Street analysts model consensus earnings of...
